US Patent

US11497737 — Pharmaceutical compositions of albumin and rapamycin

Formulation · Assigned to Abraxis Bioscience LLC · Expires 2040-10-28 · 14y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of albumin and rapamycin, specifically nanoparticles suitable for treating diseases like cancer.

USPTO Abstract

The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin. The compositions (such as pharmaceutical compositions) have specific physicochemical characteristics and are particularly suitable for use in treating diseases such as cancer. Also provided are methods of making and methods of using the compositions (such as pharmaceutical compositions).

Drugs covered by this patent

Patent Metadata

Patent number
US11497737
Jurisdiction
US
Classification
Formulation
Expires
2040-10-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.